ストックスクリーナーアプリを入手
4.93
1.00%
-0.05
アフターアワーズ：
4.93
前日終値:
$4.98
開ける：
$4.98
24時間の取引高:
154.27K
Relative Volume:
0.48
時価総額：
$184.92M
収益：
$147.12M
当期純損益:
$-33.88M
株価収益率:
-4.6409
EPS:
-1.0623
ネットキャッシュフロー:
$2.63M
1週間 パフォーマンス:
+12.05%
1か月 パフォーマンス:
-5.74%
6か月 パフォーマンス:
-35.47%
1年 パフォーマンス:
-26.09%
1日の値動き範囲:
$4.91
$5.15
1週間の範囲:
$4.22
$5.15
52週間の値動き範囲:
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Compare LFCR vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.93 | 186.80M | 147.12M | -33.88M | 2.63M | -1.0623 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | アップグレード | Barrington Research | Mkt Perform → Outperform |
| 2025-09-04 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-05-21 | 開始されました | William Blair | Outperform |
| 2024-09-05 | 開始されました | Craig Hallum | Buy |
| 2024-08-28 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | ダウングレード | Stephens | Overweight → Equal-Weight |
すべてを表示
Lifecore Biomedical Inc (LFCR) 最新ニュース
LFCR Q1 2026 Earnings: Wider Loss Than Expected Despite Positive Stock ReactionGlobal Trading Community - Newser
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference - Sahm
LFCR Stock Price, Quote & Chart | LIFECORE BIOMEDICAL INC (NASDAQ:LFCR) - ChartMill
Lifecore CEO, CFO to meet investors at June 2-4 Chicago conference - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 Earnings Miss by Significant: Key TakeawaysCollaborative Trading Signals - Newser
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
Lifecore targets 12% revenue CAGR through 2029 as midterm pipeline milestones shift - MSN
Lifecore reaffirms 2026 guidance of $120M-$125M revenue and $20.5M-$25M adjusted EBITDA while targeting 12% revenue CAGR by 2029 - MSN
Lifecore Biomedical to Participate at CDMO Live Europe - The Manila Times
TradingKey - TradingKey
The sustainable advantages Lifecore Biomedical (LFCR) is developing (+0.42%) 2026-05-10Fast Rising Stocks - newser.com
Number of shareholders of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) price target decreased by 25.71% to 6.63 - MSN
LFCR Lifecore Biomedical shares slide 3.83% as Q1 2026 earnings miss estimates by 75.7% despite modest revenue growth.Social Momentum Signals - newser.com
The steady strength in Lifecore Biomedical (LFCR) story (Softens) 2026-05-08Company Analysis - newser.com
Lifecore Biomedical Q1 2026 Earnings Call Transcript - Sahm
Barrington Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Maintains Target Price $6 - Moomoo
MSN Money - MSN
Lifecore Biomedical: Q1 Earnings Snapshot - theheraldreview.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LFCR) 2026-05-06 - Seeking Alpha
Lifecore Biomedical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Keybanc Initiates Coverage of Lifecore Biomedical (LFCR) with Sector Weight Recommendation - MSN
Lifecore Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifecore Biomedical Q1 Earnings Call Highlights - Yahoo Finance
LFCR: Revenue fell 34% in Q1 2026, but cost controls and new programs support reaffirmed 2026 guidance - TradingView
Lifecore Biomedical 1Q 2026: Revenue $23.19M, EPS ($0.43) — 10-Q Summary - TradingView
Lifecore (NASDAQ: LFCR) posts 34% revenue drop and high debt load - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 revenue drops but 2026 outlook reaffirmed - Stock Titan
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update - The Manila Times
Lifecore Biomedical Q1 revenue falls 34%, misses analyst estimates - TradingView
Lifecore lands 3 new transfer programs while cutting operating costs - Stock Titan
Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026 - The Manila Times
Before the bell May 6, Lifecore releases Q1 results, holds 8 a.m. webcast - Stock Titan
Barrington Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Raises Target Price to $6 - Moomoo
Laughing Water Capital’s Insights on Lifecore Biomedical (LFCR) - Insider Monkey
[DEF 14A] LIFECORE BIOMEDICAL, INC. DE Definitive Proxy Statement - Stock Titan
Lifecore Biomedical Inc (LFCR) 財務データ
収益
当期純利益
現金流量
EPS
1.92%
4.44%
大文字化:
|
ボリューム (24 時間):